Mindray Medical (MR) Misses Q4 EPS by 2c, Revenue Falls Short, Offers Guidance

Mindray Medical (NYSE: MR) reported Q4 EPS of $0.50, $0.02 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $399 million versus the consensus estimate of $407.07 million.

Business Outlook for Full Year 2015

The company anticipates its full year 2015 net revenues to grow by a mid-single digit percentage over its full year 2014 net revenues. The company also expects its full year 2015 non-GAAP net income to decrease by a high-single digit percentage over its full year 2014 non-GAAP net income. This guidance excludes the tax benefits related to the nationwide key software enterprise status and assumes a corporate income tax rate of 15% applicable to the Shenzhen subsidiary.

The company expects its capital expenditure for 2015 to be around $150 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

For earnings history and earnings-related data on Mindray Medical (MR) click here.

You May Also Be Interested In

• Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
• Rani Therapeutics Holdings, Inc. (RANI) Tops Q2 EPS by 1c
• Amaya (AYA) Misses Q2 EPS by 16c